Kewaunee Scientific Corporation
KEQUConsumer CyclicalNASDAQFurnishings, Fixtures & Appliances · Last scanned Oct 26, 2026
Scan Results
Daily timeframeKewaunee Scientific Corporation, together with its subsidiaries, designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products in the United States. Valued at $94.9M, KEQU is a micro-cap name in its sector. It operates through two segments, Lab Products Group (LPG) and International.
Market Cap
$94.9M
Beta
0.76
P/E (TTM)
11.88
P/E (Fwd)
15.18
EPS (TTM)
$2.76
EPS (Fwd)
$2.16
ROE
12.5%
ROA
5.1%
Cash
$8.2M
Total Debt
$55.5M
Free CF
$9.2M
52W Change
-25.8%
Annual Financials
Cash vs Debt
Where KEQU stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, KEQU finished 8.37% below its 150-day moving average ($36.21) and 10.57% below its 200-day moving average ($37.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KEQU overbought or oversold?
At the October 15, 2026 close, KEQU's RSI(14) was 38.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $8.2M in cash, though total debt stands at $55.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $9.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 12.5%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $219.5M (2023) to $282.0M (2026), reflecting a 28% increase over the period.
Kewaunee Scientific Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing KEQU.